GRFT抑制尼帕病毒入侵与融合并可保护叙利亚金仓鼠
本研究评估了GRFT及其三聚体衍生物3mG对尼帕病毒(NiV)等4个病毒科的体外抗病毒活性,3mG因更强阻断NiV糖蛋白诱导的合胞体形成而优于GRFT;氧化耐受型Q-GRFT在叙利亚金仓鼠致死性NiV攻击中显示出显著保护作用。
要点
- 3mG体外抑制NiV的效力优于GRFT,机制为阻断糖蛋白诱导的合胞体形成。
- 氧化耐受型Q-GRFT在叙利亚金仓鼠致死性NiV攻击中显示显著保护。
- GRFT与3mG值得进一步开发为潜在的NiV治疗药物。
核心结论
- GRFT及其衍生物3mG具有抗NiV活性,Q-GRFT在叙利亚金仓鼠致死性攻击模型中显示显著保护,支持进一步开发为NiV候选疗法。
研究设计与样本
- 体外评估GRFT与合成三聚体串联体3mG对NiV及4个病毒科其他病毒的抗病毒活性。
- 在叙利亚金仓鼠中进行Q-GRFT对致死性NiV攻击的初始体内预防性评价。
主要发现
- 3mG对NiV的效力相对强于GRFT,归因于其更强阻断NiV糖蛋白诱导的合胞体形成。
- 氧化耐受型Q-GRFT在叙利亚金仓鼠致死性NiV攻击中显示显著保护。
临床怎么用
- 目前尚无获批的人用NiV治疗药物,GRFT与3mG为候选抗NiV疗法提供临床前依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus that causes fatal encephalitis and respiratory disease in humans. There is currently no approved therapeutic for human use against NiV infection. Griffithsin (GRFT) is high-mannose oligosaccharide binding lectin that has shown in vivo broad-spectrum activity against viruses, including severe acute respiratory syndrome coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus. In this study, we evaluated the in vitro antiviral activities of GRFT and its synthetic trimeric tandemer (3mG) against NiV and other viruses from 4 virus families. The 3mG had comparatively greater potency than GRFT against NiV due to its enhanced ability to block NiV glycoprotein-induced syncytia formation. Our initial in vivo prophylactic evaluation of an oxidation-resistant GRFT (Q-GRFT) showed significant protection against lethal NiV challenge in Syrian golden hamsters. Our results warrant further development of Q-GRFT and 3mG as potential NiV therapeutics.
引用
- Lo MK, Spengler JR, Krumpe LRH, et al. Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge. J Infect Dis. 2020. PMID: 32037447. doi:10.1093/infdis/jiz630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。